RP-182

RP-182 is a synthetic immunomodulatory peptide that exerts antitumor effects by targeting the mannose receptor CD206 on the surface of tumor-associated macrophages (TAM) with a binding affinity (Kd) of 8 μM. It induces a conformational change in the CD206 receptor, which activates NF-κB signaling and phagocytosis in TAM with high CD206 expression. RP-182 serves a dual function by activating the canonical NF-κB signaling pathway, leading to TNFα secretion and autocrine activation of TNF receptor 1 (TNFR1), which subsequently results in caspase 8 activation and apoptosis. This compound is studied in the contexts of pancreatic cancer and melanoma.

[C@@H](CC1=CC=CC=C1)(NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC3=CC=CC=C3)NC([C@H](CCCCN)N)=O)=O)CCCNC(=N)N)=O)CCCCN)=O)C)=O)=O)CCCCN)=O)CCCNC(=N)N)=O)C(N[C@@H](CC4=CC=CC=C4)C(O)=O)=O